Simulation can be carried out at different effective plasmatic therapeutic level of the drugs to identify the level at which cardiotoxicity cannot be neglected. The data collected could be finally managed to create a score system aimed to define the torsadogenic risk, namely the risk of inducing torsade de pointes, of the new drugs.
A possible torsade de point risk score to assess cardiotoxicity could be:
where  is the sum of all concentrations, [C] is the concentration taken into account,  ,  is the total number of models in the population, and  represents the number of models showing repolarization abnormalities.